Cosmo Pharmaceuticals N.V (C43) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has a cash flow conversion efficiency ratio of 0.013x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€6.28 Million ≈ $7.35 Million USD) by net assets (€469.22 Million ≈ $548.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Cosmo Pharmaceuticals N.V worth for the company's overall valuation and market capitalisation.
Cosmo Pharmaceuticals N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cosmo Pharmaceuticals N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cosmo Pharmaceuticals N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their cash flow conversion efficiency. Explore earnings quality score of Cosmo Pharmaceuticals N.V to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shaanxi Fenghuo Electronics Co Ltd
SHE:000561
|
-0.062x |
|
Insigma
SHG:600797
|
0.030x |
|
JiangSu Jin Tong Ling Fluid Mach
SHE:300091
|
-0.044x |
|
Verve Therapeutics Inc
NASDAQ:VERV
|
-0.059x |
|
Bafang Electric Suzhou Co Ltd
SHG:603489
|
0.017x |
|
Tejas Networks Limited
NSE:TEJASNET
|
-0.154x |
|
CBL & Associates Properties Inc
NYSE:CBL
|
0.204x |
|
Yotrio Group Co Ltd
SHE:002489
|
-0.246x |
Annual Cash Flow Conversion Efficiency for Cosmo Pharmaceuticals N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cosmo Pharmaceuticals N.V from 2016 to 2025. View Cosmo Pharmaceuticals N.V (C43) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €489.18 Million ≈ $571.90 Million |
€-12.48 Million ≈ $-14.60 Million |
-0.026x | -107.94% |
| 2024-12-31 | €505.09 Million ≈ $590.50 Million |
€162.41 Million ≈ $189.88 Million |
0.322x | +286.00% |
| 2023-12-31 | €403.62 Million ≈ $471.88 Million |
€33.62 Million ≈ $39.31 Million |
0.083x | +16.28% |
| 2022-12-31 | €463.79 Million ≈ $542.22 Million |
€33.23 Million ≈ $38.84 Million |
0.072x | +191.24% |
| 2021-12-31 | €512.68 Million ≈ $599.37 Million |
€12.61 Million ≈ $14.74 Million |
0.025x | -24.20% |
| 2020-12-31 | €400.12 Million ≈ $467.79 Million |
€12.98 Million ≈ $15.18 Million |
0.032x | +167.80% |
| 2019-12-31 | €393.73 Million ≈ $460.32 Million |
€-18.85 Million ≈ $-22.03 Million |
-0.048x | -109.50% |
| 2018-12-31 | €444.85 Million ≈ $520.08 Million |
€-10.16 Million ≈ $-11.88 Million |
-0.023x | -13.93% |
| 2017-12-31 | €470.12 Million ≈ $549.62 Million |
€-9.43 Million ≈ $-11.02 Million |
-0.020x | -138.42% |
| 2016-12-31 | €415.56 Million ≈ $485.83 Million |
€21.69 Million ≈ $25.36 Million |
0.052x | -- |
About Cosmo Pharmaceuticals N.V
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more